HBV Disease Progression
High HBV Viral Load Predicts Liver Fibrosis and Cancer
- Details
- Category: HBV Disease Progression
- Published on Tuesday, 30 August 2011 00:00
- Written by Liz Highleyman
High hepatitis B virus (HBV) DNA levels were associated with worse liver fibrosis, hepatitis reactivation, and development of hepatocellular carcinoma (HCC) in hepatitis B "e" antigen (HBeAg) negative patients in 2 recent studies described in the July 2011 Journal of Viral Hepatitis.
Deferoxamine Shows Promise for Liver Cancer in People with Advanced Disease
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 12 August 2011 00:00
- Written by Liz Highleyman
Deferoxamine, a cancer drug that has an anti-proliferative effect on tumor cells, led to improvement of hepatocellular carcinoma (HCC) in 2 out of 10 patients with moderate-to-severe liver disease, according to a letter in the August 11, 2011, New England Journal of Medicine.
Does Previous Hepatitis B Exposure Increase Liver Cancer Risk?
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 14 December 2010 12:48
- Written by Liz Highleyman
People who were previously exposed to hepatitis B virus (HBV) have an increased likelihood of developing hepatocellular carcinoma (HCC) even if they clear the virus, according to a study presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) in Boston. These results suggest that individuals with prior HBV exposure, as well as those with chronic hepatitis B, could benefit from regular liver cancer monitoring.Jeffrey Tang and colleagues from Henry Ford Health System in Detroit conducted a retrospective cohort study to explore the association between hepatitis B serologic status and development of HCC among North American patients.
One-quarter of Patients Clear Hepatitis Delta with Pegylated Interferon
- Details
- Category: Hepatitis Delta (HDV)
- Published on Friday, 28 January 2011 03:30
- Written by HIVandHepatitis.com
Treatment with pegylated interferon (Pegasys) -- either alone or in combination with the antiviral drug adefovir (Hepsera) -- led to clearance of hepatitis delta virus (HDV) and improvement in liver enzyme levels, according to a small study published in the January 27, 2011, New England Journal of Medicine. Adefovir alone, however, had no effect on HDV.
Artificial Liver Device Improves Survival for Hepatitis B and C Patients with Decompensated Disease
- Details
- Category: Liver Transplant - HBV
- Published on Tuesday, 14 December 2010 12:48
- Written by Vital Therapies
An artificial liver device known as ELAD -- which runs a patient's blood through cartridges containing human liver cells -- conferred a significant survival advantage for people with acute decompensated liver disease related to chronic hepatitis B or C, according to a Chinese study presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) in Boston. After 3 years, 44% of ELAD users were still alive without liver transplants, compared with 18% in the standard therapy group.
More Articles...
- Alcohol and Diabetes Increase Risk of Liver Disease Progression in Hepatitis B Patients
- Androgen Receptor May Explain Why More Men with Hepatitis B Develop Liver Cancer
- Sex Hormone Receptor May Explain Higher Risk of Hepatocellular Carcinoma in Men
- EASL 2010: Measurable Neurocognitive Impairment Persists after Episodes of Hepatic Encephalopathy in People with Liver Cirrhosis
Web Design and Development by